Swiss Medica, Inc.
OTC Bulletin Board : SWME

Swiss Medica, Inc.

July 31, 2006 08:00 ET

Swiss Medica's O24 Pain Neutralizer Enhances Workplace Productivity

TORONTO, ONTARIO--(CCNMatthews - July 31, 2006) - Swiss Medica, Inc. (OTCBB:SWME) announced today that Fenco Automotive, a Canadian aftermarket automotive manufacturer with over 1,200 employees, has found that its factory workers are finding fast and effective pain relief using Swiss Medica's O24 Pain Neutralizer to manage their employees repetitive work strain and musculoskeletal disorders.

According to Marisa Cornacchia, R.N., the occupational health nurse for Fenco:

"With the introduction of O24 spray and wipes employees are now receiving effective pain control that helps them through their workday comfortably. O24 spray has been successfully treating the many different body areas of repetitive work strain and has been able to offer our workers an alternative to pain pills.

O24 has helped with our new program development to maximize worker health and keep our employees at work. Also the small wipe package are convenient for the employees to keep at the work station and apply it themselves, therefore encouraging self care for pain and minimizing visits to the nursing office. It has also been easier to maintain and restore the physical and psychosocial well being of our employees.

O24 has allowed our employees to maintain a comfort zone in their jobs by enabling them to manage their pain during their workday. This has been extremely beneficial in reducing absenteeism."

Grant Johnson, President and COO of Swiss Medica stated "it is our goal to have O24 used as the gold standard pain reliever within manufacturing environments where workers' safety and repetitive work strain and pain disorders are a growing concern. Medical Practitioners and consumers are telling us that they have safety concerns about oral pain relief products, especially in light of the recent study that appeared recently in the Journal of the American Medical Association. This clinical study raised concerns about people taking eight extra-strength acetaminophen tablets a day over a two week period. The study showed that 40% of the test subjects taking acetaminophen had abnormal test results that would signal liver damage, while the patients taking placebos over the same time showed no adverse liver test results".

About Swiss Medica, Inc.

Swiss Medica is a specialty pharmaceutical company focused on commercializing over-the-counter clinically-tested, patented all-natural products that relieve chronic ailments. Swiss Medica builds its brands through innovative and focused distribution and marketing strategies. Swiss Medica's mission is to be a world leader in the commercialization of over-the-counter, safe and effective chronic ailment treatments. Please visit our websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com.

Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used and recommended for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available over-the-counter throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

Swiss Medica has recently launching the patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Over 10 million Americans suffer from the long-term pain associated with Fibromyalgia. In a randomized double blind clinical trial conducted in 2005, 88 per cent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest retailer.

Swiss Medica also distributes PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to acceptance of Swiss Medica's products in Canada, the United States and other countries, risks related to international sales and purchases and potential foreign currency exchange fluctuations, acceptance of Swiss Medica's products, increased levels of competition, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information